Lauren Silvernail
Sticking with new Chief Financial Officers, biopharmaceutical company Revance Therapeutics has appointed Lauren Silvernail. Silvernail, who succeeds David Styka in the role, will also serve as Executive Vice President of Corporate Development effective immediately and comes direct from the same title at ISTA Pharmaceuticals.
“As an experienced Chief Financial Officer and executive in the biopharmaceutical field, Lauren has demonstrated strength in strategy and execution and she will be an instrumental member of the organization,” said Dan Browne, Revance’s President and CEO.